1) is trialling PXS 5505 with ruxolitinib transferrable to other JAK inhibitors ? if not, it restricts potential acquirers to that drug co ?
2) if PXS 5505 is successful with current ruxolitinib trial it still requires a phase 2b and 3 trial, but SNT will be running out of cash at that point so potentially a CR albeit above .022 cents
3) difficult to progress other assets as quickly as 5505
Risk On
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $22.68M | |||
| Open | High | Low | Value | Volume |
| 2.0¢ | 2.0¢ | 1.9¢ | $62.08K | 3.202M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 2285220 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 443250 | 1 |
View Market Depth
| Last trade - 15.11pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
1.9¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 1.9¢ | 2.0¢ | 1.8¢ | 1339953 | ||
| Last updated 15.15pm 27/05/2024 ? | |||||
| SNT (ASX) Chart |